Clinical Trial Update: PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for PF-07265028 as a single agent and in combination with sasanlimab in advanced/metastatic solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Urothelial Cancer

Drugs mentioned

• PF-07265028
• Sasanlimab (sasanlimab)

Snippet

Sponsor: Pfizer | Conditions: Advanced Solid Tumors, Gastric Cancer | Phase 1 | Status: TERMINATED